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Abstract
Background: Even though addressing lifestyle problems is a major recommendation in most guidelines for the
treatment of hypertension (HTN), alcohol problems are not routinely addressed in the management of hypertension
in primary health care.
Methods: Internet based survey of 3081 primary care physicians, recruited via the mailing lists of associations for
general practitioners (GPs) in France, Germany, Italy, Spain and the UK. Clinical practice, attitudes, knowledge,
education and training were assessed. Logistic regression to predict screening, brief intervention and treatment for
alcohol dependence in the management of hypertension were assessed.
Results: Overall, about one third of the interviewed GPs reported sufficient screening in cases with HTN (34.0 %,
95 % confidence interval (CI):32.1–35.8 %). One out of five GPs screened and delivered brief interventions in HTN
patients with hazardous consumption (22.2 %, 95 % CI: 20.6–23.8 %) and about one in 13 GPs provided treatment
for HTN patients with alcohol dependence other than advice or brief intervention (7.8 %, 95 % CI: 6.8–8.9 %).
Post-graduate training and belief in their effectiveness predicted interventions. There were marked differences
between countries.
Conclusions: While current interventions were overall low, marked differences between countries indicate that
current practices could be improved. Education and post-graduate training seems to be key in improving
clinical practice of including interventions for problematic alcohol consumption and alcohol dependence in
primary health care.
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Background
Hypertension (HTN) is the single most important risk
factor for mortality and burden of disease, globally and
especially for high income countries in Europe [1]. Its main
effect is on cardiovascular outcomes, and consequently, re-
duction of blood pressure is among the risk factor targets
of the World Health Organisation ‘Global Action Plan for
Prevention and Control of Non-communicable Diseases’
for the period 2013–2020 [2]. Primary health care has trad-
itionally had a key role in the detection and the manage-
ment of HTN [3]. Part of this management involves advice
and interventions on lifestyle factors underlying HTN,
and guidelines recommend lifestyle changes as important
means to reduce blood pressure, prevent and/or avoid
medication for HTN [3–5]. Both epidemiology and ran-
domized trials converge in demonstrating that alcohol
consumption, in particular heavy drinking, is one of the
most important lifestyle based risk factors for HTN [6–9].
However, the mortality and disease burden attributable
to HTN has increased globally since 1990 [1] and large
European surveys still show a large proportion of adults
with uncontrolled HTN (http://apps.who.int/gho/data/
?theme=home), indicating the need for further action. Of
all lifestyle factors, alcohol seems to be the least inter-
vened in the management of HTN [10–13], which is no
surprise given the low screening and intervention rates for
hazardous drinking and alcohol use disorder in primary
health care [14, 15]. Interventions for hazardous drinking
are scarce [15–17]; and alcohol use disorders have the
lowest treatment rate of all mental disorders [18–20],
despite evidence that there are effective interventions
available for both hazardous drinking and for alcohol
use disorders [21, 22], which could be implemented
at the primary care level [23, 24].
Thus, improving alcohol interventions in primary
health care promises to yield substantial health benefits
[10–13, 25]. The main question to realize this potential
is how to best implement such interventions [23], both
for hazardous drinking and for alcohol use disorders, as
part of routine management of HTN. Together with pri-
mary care associations in the five largest countries in the
European Union (France, Germany, Italy, Spain, and the
United Kingdom (UK)), we developed a survey of gen-
eral practitioners (GPs) to explore knowledge, attitudes
and clinical practice of lifestyle interventions in the man-
agement of HTN and to help a potential implementation
of alcohol interventions (Baseline Alcohol Screening and
Intervention Survey (BASIS)).
Methods
Design of the BASIS survey and pilot
All authors were involved in drafting and finalizing the
survey, originally in English. After an empirical pilot
study in five countries (N = 41 respondents), the survey
was translated into French, German, Italian, and Spanish
and the national versions were again tested and finalized
with the help of local experts. A brief summary of the
survey and its subsections are given in Additional file 1.
It contained 28 core items (in addition to a few country-
specific items) and was put online in all languages
using SurveyMonkey (http://www.surveymonkey.com).
The English version of the survey can be found on-
line (Additional file 2). The theoretical basis was the
Information-Motivation-Behavioural Skills model [26, 27],
which stipulates that information and education is not suf-
ficient to adopt behaviours; in addition there needs to be
motivation and behavioural skills. This model had been
adopted to care of non-communicable diseases [28].
Survey implementation
In each of the five countries, regional or nationwide GP
associations disseminated the web link to the survey to
their members, mainly via electronic mail (for details see
Table 1). The median completion time was 8.8 min, with
a span from under 2 min to over an hour). Four responses
were removed from the data set due to suspicion of being
duplicates. The entire survey was answered by 2468 re-
spondents (80.1 % of those who started: 3081) between
September 29 and December 1, 2015.
The survey included a number of free text items, includ-
ing descriptions how alcohol problems were managed. A
coding scheme based on free text responses given in
Germany and the UK was developed and subsequently all
such responses were classified by two independent raters
for each language. Kappa agreement coefficients were
calculated and ranged from 0.31 to 1 in the variables
analyzed. Non-concordant ratings were revisited and a
final decision was made by JM.
Statistical analyses
Three different indicators for good practice alcohol
management in patients with HTN were derived from
responses given in the questionnaire: a) sufficient
screening for alcohol use (at least 7 out of 10 HTN pa-
tients); b) sufficient screening (as above) in addition to
management of alcohol problems in hypertensive pa-
tients with hazardous drinking levels by the GP them-
selves or within the same practice usually with brief
interventions (for rationale see care [21, 29]; c) sufficient
screening and management of alcohol dependence in
hypertensive patients by the GPs themselves or within
the same practice. Indicator c was only met if GPs did
not only offer brief advice or counselling as management
for alcohol dependence but also reported other interven-
tions, such as psychotherapy, or pharmacotherapy. This
operationalization was chosen, as current guidelines do
not recommend brief advice only as a treatment inter-
vention for dependence [30, 31].
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Logistic regressions on each indicator were computed
with Stata 14.0 [32], using the following variables as co-
variates (specifications in parentheses): age (categories as
dummy variables with ‘70 or older’ as reference cat-
egory), sex, country (dummy coded with UK as reference
category), beliefs about success of different lifestyle in-
terventions for hypertension (questionnaire items 3 and
4: dummy variables, each scored 1 if rated (highly) suc-
cessful, else 0), knowledge (questionnaire item 1: dummy
variable, scored 1 if alcohol was selected as important
risk factor for HTN, else 0), education (questionnaire
items 24 and 27: dummy variables, each scored 1 for at
least 4 out of 5 points on Likert scale regarding ad-
equacy of graduate education on alcohol/HTN, else 0;
questionnaire items 25 and 28: dummy variables, each
scored 1 if post-graduate education on alcohol, HTN
was received, else 0), and workload (questionnaire item 7:
continuous variable containing number of daily patient
contacts, z-standardized for each country to achieve com-
parability). A measure of the respondents’ drinking patterns
(questionnaire items 32–34) was also considered for inclu-
sion in the models. However, it was decided against it as it
would have overly limited the generalizability of the find-
ings by reducing the sample size by 24 % (from 2468 to
1885) because these items were not assessed among UK re-
spondents and responses were not required to complete
the survey in the remaining countries.
Results
Two thousand four hundred sixty eight health profes-
sionals participated in the survey (for details see Table 1).
With respect to the indicators of good practice alcohol
management (= main dependent variables), Table 2 gives
the prevalence by country.
The overview of influencing variables for good practice
alcohol management are given in Table 3, where the
reference country was always the UK. Clearly screening
for alcohol was best implemented in the UK and Spain,
management of hazardous drinking levels was best im-
plemented in Spain (87 % of all identified GPs treated
Table 1 Assessment details by country
Country Region of drawn sample Local responsibles Incentives Response ratea Number of
complete responses
France National sample SFMG None 8.5 % 512
Germany Mostly Bavariab BHÄV No personal incentives;
€15 paid to BHÄV suborganisation
2.3 % 103
Hamburg CIAR €15 voucher 7.9 % 88
Italy National sample SIMG None 10.1 % 360
Spain National sample semFYC None 9.4 % 802
National sample semergen None 1.1 % 95
UK National sample MediConf £10 voucher 4.1 % 508
Total 5.7 % 2468
Note. SFMG Société Française de Médecine Générale, BHÄV Bayerischer Hausärzteverband, CIAR Centre for Interdisciplinary Addiction Research, SIMG Società
Italiana di Medicina Generale, semFYC Sociedad Española de Medicina de Familia y Comunitaria. semergen = Sociedad Española de Médicos de Atención Primaria
aRefers to number of any response among all contacted individuals
bAn advertisement in a nationwide newspaper was placed during the period of data collection with very little response. Out of 103 GPs, 98 were from Bavaria and the
remaining five from Hesse (1), North Rhine-Westphalia (2) and Saxony (2). The response rate was calculated by omitting the 54,000 potential readers from the denominator














Proportion of GPs screening at least 7 out of
10 hypertensive patients for alcohol % (CI)
5.9 (4.1–8.3) 26.7 (20.9–33.4) 36.1 (31.3–41.2) 45.8 (42.6–49.1) 42.5 (38.3–46.9) 34.0 (32.1–35.8)
Indicator B:
Proportion of GPs with sufficient screening (as A)
and self-management of alcohol problems in
patients with hazardous drinking levels % (CI)
4.5 (3.0–6.7) 18.8 (13.9–25.0) 26.1 (21.8–30.9) 35.0 (32.0–38.2) 15.7 (12.8–19.2) 22.2 (20.6–23.8)
Indicator C:
Proportion of GPs with sufficient screening (as A)
and self-management of alcohol problems in
patients with alcohol dependence a % (CI)
2.0 (1.0–3.6) 14.1 (9.9–19.8) 3.6 (2.1–6.1) 13.2 (11.1–15.5) 4.7 (3.2–7.0) 7.8 (6.8–8.9)
Notes. GP General Practitioner
aTreatment of alcohol problems only via brief intervention or advice did not qualify as indicator for sufficient alcohol management
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only via brief interventions/advice), and treatment of
alcohol dependence was best implemented in Spain and
Germany. As hypothesized, post-graduate education and
the belief that lifestyle interventions were successful in
avoiding HTN-related prescriptions seem to impact on
all three indicators. For screening and management of
hazardous drinking levels, the GPs’ knowledge about the
importance of alcohol as a risk factor for HTN was also
positively related.
Discussion
In this large survey, we found that alcohol interventions
were relatively scarce in European primary health care.
Overall, about one third of the interviewed GPs reported
sufficient screening in cases with HTN. One out of five
GPs screened and delivered brief interventions in HTN pa-
tients with hazardous consumption and about one of 13
GPs provided treatment for HTN patients with alcohol de-
pendence other than advice or brief intervention. There
were marked differences between European countries
though, with most of the screening and interventions been
given in Spain and the UK, and least in France. Compared
to British GPs, only a fraction of the French colleagues
reported sufficient alcohol screening (OR = 0.08), and only
every 50th French GP reported sufficient screening and al-
cohol management in alcohol dependent patients on their
own. We can only speculate about the reasons for the
French situation, but it may have to do with lack of guide-
lines. The French guidelines for HTN treatment developed




as the authors’ conflict of interest statements did not meet
later introduced rules (http://www.has-sante.fr/portail/up-
load/docs/application/pdf/2011-09/cp_recos_suspendues_
19092011_vdef.pdf ). In general, the notion of the benefi-
cial effects of alcohol on cardiovascular outcomes is strong
Table 3 Prediction of good practice alcohol management
N = 2468 Model Aa Model Ba Model Ca
Pseudo R2 .1208 .1164 .1113
Predictors: OR p OR p OR p
Sex: 0 =male, 1 = female 0.80 (0.66–0.97) .026 1.15 (0.92–1.42) .221 1.22 (0.88–1.68) .232
Age: less than 30 years old 0.66 (0.21–2.10) 0.71 (0.20–2.54) 1.20 (0.14–10.57)
Age: 30–39 years old 0.91 (0.31–2.67) 0.69 (0.21–2.28) 0.97 (0.12–7.81)
Age: 40–49 years old 0.96 (0.33–2.83) 0.75 (0.23–2.78) 0.84 (0.10–6.77)
Age: 50–59 years old 0.88 (0.30–2.58) 0.72 (0.22–2.34) 1.19 (0.15–9.42)
Age: 60–69 years old 0.97 (0.33–2.87) 0.89 (0.27–2.94) 1.10 (0.13–8.88)
Age: at least 70 years old (reference categoryb) 1 .734 1 .791 1 .714
Country: only France 0.08 (0.05–0.12) 0.20 (0.12–0.32) 0.32 (0.14–0.67)
Country: only Germany 0.43 (0.29–0.63) 1.04 (0.66–1.65) 2.79 (1.51–5.18)
Country: only Italy 0.68 (0.49–0.96) 1.48 (0.99–2.21) 0.50 (0.23–1.08)
Country: only Spain 0.98 (0.76–1.27) 2.57 (1.88–3.51) 2.45 (1.48–4.06)
Country: UK (reference categoryb) 1 <.001 1 <.001 1 <.001
Belief: Patients successfully reduced blood pressure due to lifestyle change 1.21 (0.96–1.52) .098 1.18 (0.92–1.51) .198 1.70 (1.19–2.42) .003
Belief: Lifestyle changes successful to avoid prescribed HTN medication 1.42 (1.17–1.73) <.001 1.44 (1.15–1.79) .001 1.48 (1.07–2.06) .019
Knowledge: alcohol rated as important risk factor for HTN 1.27 (1.01–1.60) .043 1.43 (1.10–1.86) .007 1.21 (0.82–1.79) .332
Education: university education on alcohol was sufficient 1.41 (1.05–1.90) .022 1.34 (0.97–1.86) .079 1.25 (0.78–2.02) .353
Education: received post-graduate education on alcohol 1.49 (1.23–1.80) <.001 1.93 (1.55–2.40) <.001 2.49 (1.75–3.54) <.001
Education: university education on HTN was sufficient 0.91 (0.75–1.09) .301 1.04 (0.84–1.29) .702 0.95 (0.67–1.31) .752
Education: received post-graduate education on HTN 1.32 (0.98–1.75) .052 1.32 (0.93–1.89) .123 1.05 (0.59–1.87) .865
Workload: country-standardized measure of daily patient contacts 1.02 (0.94–1.12) .597 1.02 (0.92–1.12) .718 1.02 (0.90–1.16) .752
Notes. HTN Hypertension
aLogistic regression models predicted alcohol management using different indicators: For Model A, sufficient screening, i.e. at least 7 out of 10 HTN patients was
predicted. For Model B and C, composite indicators consisting of sufficient screening (as Model A) in addition to self-management of alcohol problems in hypertensive
patients with either hazardous drinking levels (Model B) or alcohol dependence (Model C) was predicted. For Model C, treatment of alcohol problems only via brief
intervention or advice did not qualify as indicator for sufficient alcohol management
bFor age and country, the p-values refer to an omnibus test for the entire variable, i.e., testing the global hypotheses that the coefficient for any age category or
country deviates from the null hypothesis of no difference above chance
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(“French paradox”; see [33]; see also the official training
materials of the French cardiologists [34]). The lack of
knowledge and training in Italian GPs with respect to
screening and brief interventions has been found in several
other European studies (INEBRIA: AMPHORA: [35]; see
also http://www.epicentro.iss.it/alcol/apd2013/presenta-
zioni/9.Cuffari.pdf ), and has seemingly not improved over
the past years.
Before we discuss potential conclusions of the results,
we would like to highlight limitations. First, response
rates are relatively low. While it is hard to compare re-
sponse rates across physicians’ surveys, as there are differ-
ent sampling frames and several web-based surveys do
not even give response rates [36, 37], and even though
web-based surveys have comparably lower response rates
[38], an overall response rate of 6 % must be considered
low. As a consequence, while the national/regional sam-
pling frames can be considered as representative, the low
response rates suggest that a convenience sample of GP’s
being more motivated and interested in the topic has been
drawn [39]. Thus the screening and intervention rates re-
ported are likely to be overestimates (for intervention
rates in samples of GP’s with representative sampling and
a considerably higher response rate [14, 40]). Second, all
answers were self-reports and social desirability bias may
have shifted some of our key results upwards [41]. In
other words, based on the two major limitations of this
study, the rates for screening and interventions among
hypertensive primary health care patients in Europe are
most likely lower than described in this study. However,
given the low response rate, we cannot fully rule out that
we have underestimated the GPs’ involvement, e.g., if en-
gaged GPs were too busy to participate in our survey.
Conclusions
While our findings are susceptible to sample distortion,
they are sufficiently robust to demonstrate that the GPs’
involvement in alcohol screening and management
among patients with HTN is generally poor in the lar-
gest European countries. Thus, the situation for HTN
patients is likely not better than for other primary care
patients with respect to detection of and interventions for
heavy drinking and alcohol use disorders [14, 15, 17, 40].
What can be done about this? First, medical education at
universities have to put more emphasis on alcohol as one
of the main risk factors for many disease conditions GPs
see in their daily practice [40]. The lack of education
seems a common problem in all five countries, and was
also highlighted in some of the qualitative answers.
Moreover, post-graduate training was shown to increase
screening and intervention rates [16, 42], and this is,
where GP associations can contribute. Secondly, given
the high overall workload of GPs, and the overall health
burden attributable to alcohol in countries in the European
Union [20], alcohol interventions need to be prioritized
and this could be done by financial incentives. A recent
cluster randomized trial with 746 providers in 120 primary
health care centers from five European countries has
shown that modest financial incentives increase screening
and intervention rates. Interestingly, there is a synergistic
effect when financial incentives, training and support are
offered together [17]. We hope that the involvement of
several GP associations in the current study will help over-
come these barriers in the future.
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